Oregovamab Uses, Dosage, Side Effects and more
Oregovamab is a murine monoclonal antibody that attaches to the tumor-associated antigen CA125.
Oregovamab is well tolerated and induces multiple antigen-specific immune responses, maintained during concomitant chemotherapy. A significant survival benefit has been observed in patients mounting a T-cell response to CA125 and/or autologous tumor. Vaccination with oregovomab may stimulate a host cytotoxic immune response against tumor cells that express CA125.
| Trade Name | Oregovamab |
| Generic | Oregovomab |
| Oregovomab Other Names | Monoclonal antibody B43.13, Oregovamab, Oregovomab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in ovarian cancer.
How Oregovamab works
Oregovamab targets the circulating tumour-associated antigen CA 125, which is shed from the surface of human ovarian cancer cells; the antibodies induce broad cellular and humoral immune responses against CA 125 via complex formation. Unlike free CA 125, CA 125-oregovomab complexes can prime dendritic cells, leading to downstream activation of T cells.
